Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vigil Neuroscience Inc (VIGL)
NASDAQ:VIGL
VIGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.49 - $6.06
Previous CloseN/A
Volume101.11K
Average Volume (3M)1.89M
Market Cap
$118.14M
Enterprise Value$39.87M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Mar 20, 2025EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.07
Shares Outstanding40,879,486
10 Day Avg. Volume406,508
30 Day Avg. Volume1,888,008
Standard Deviation0.38
R-Squared0.06
Alpha-0.00322
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)6.80
P/FCF Ratio6.80
Enterprise Value/Market Cap0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-99.93
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$14.53Price Target Upside402.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Vigil Neuroscience Inc News
PremiumCompany Announcements
Vigil Neuroscience Announces Positive Phase 1 Trial Results
PremiumCompany Announcements
Vigil Neuroscience Advances Key Clinical Programs
---
Bulls Say, Bears Say
Bulls Say
Partnership ProspectsThe likelihood that Vigil Neuroscience strikes a large Alzheimer's disease-focused partnership deal for VG-3927 before the Phase 2 study start is quite high.
Safety And EfficacyVG-3927 showed a very safe and well-tolerated profile, with excellent PK/PD properties and robust target engagement.
Treatment PotentialVG-3927 has the potential to become a best-in-class treatment for Alzheimer's disease, given its ability to be dosed orally and lower ARIA potential.
Bears Say
Competitive LandscapeAnalyst reiterates a Market Outperform rating for Vigil Neuroscience despite negative AL002 results.
Market SentimentThere is likely near-term negative sentiment on the TREM2 target, possibly affecting VIGL shares.
Stock PerformanceVigil Neuroscience's shares are trading higher on the news, but the current stock move understates the positivity of the data, suggesting potential for further growth.
---
Ownership Overview
32.44% Insiders
3.02% Mutual Funds
37.48% Other Institutional Investors
24.59% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VIGL FAQ
What was Vigil Neuroscience Inc’s price range in the past 12 months?
Vigil Neuroscience Inc lowest stock price was $1.49 and its highest was $6.06 in the past 12 months.
What is Vigil Neuroscience Inc’s market cap?
Vigil Neuroscience Inc’s market cap is $118.14M.
When is Vigil Neuroscience Inc’s upcoming earnings report date?
Vigil Neuroscience Inc’s upcoming earnings report date is Mar 20, 2025 which is in 26 days.
How were Vigil Neuroscience Inc’s earnings last quarter?
Vigil Neuroscience Inc released its earnings results on Nov 07, 2024. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.545 by $0.075.
Is Vigil Neuroscience Inc overvalued?
According to Wall Street analysts Vigil Neuroscience Inc’s price is currently Undervalued.
Does Vigil Neuroscience Inc pay dividends?
Vigil Neuroscience Inc does not currently pay dividends.
What is Vigil Neuroscience Inc’s EPS estimate?
Vigil Neuroscience Inc’s EPS estimate is -0.54.
How many shares outstanding does Vigil Neuroscience Inc have?
Vigil Neuroscience Inc has 40,879,486 shares outstanding.
What happened to Vigil Neuroscience Inc’s price movement after its last earnings report?
Vigil Neuroscience Inc reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.545. Following the earnings report the stock price went down -6.299%.
Which hedge fund is a major shareholder of Vigil Neuroscience Inc?
Currently, no hedge funds are holding shares in VIGL
---
Vigil Neuroscience Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.53 (402.77% Upside)
$14.53 (402.77% Upside)
Blogger Sentiment
Bullish
VIGL Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $49.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.07%
12-Months-Change
Fundamentals
Return on Equity
-73.62%
Trailing 12-Months
Asset Growth
-17.52%
Trailing 12-Months
Company Description
Vigil Neuroscience Inc
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.
---
VIGL Stock 12 Month Forecast
Average Price Target
$14.53
▲(402.77% Upside)
Technical Analysis
Alnylam Pharma
―
Biogen
―
Ionis Pharmaceuticals
―
SAGE Therapeutics
―
Denali Therapeutics
―
Best Analysts Covering VIGL
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-27.93%
reiterated a buy rating last month
Copying Graig Suvannavejh's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -27.93% per trade.
---